Schizophrenia is a chronic, severe and highly complex mental illness. Current treatments manage the positive symptoms, yet have minimal effects on the negative and cognitive symptoms, two prominent features of the disease with critical impact on the long-term morbidity. In addition, antipsychotic treatments trigger serious side effects that precipitate treatment discontinuation. Here, we show that activation of the trace amine-associated receptor 1 (TAAR1), a modulator of monoaminergic neurotransmission, represents a novel therapeutic option. In rodents, activation of TAAR1 by two novel and pharmacologically distinct compounds, the full agonist RO5256390 and the partial agonist RO5263397, blocks psychostimulantinduced hyperactivity and produces a brain activation pattern reminiscent of the antipsychotic drug olanzapine, suggesting antipsychotic-like properties. TAAR1 agonists do not induce catalepsy or weight gain; RO5263397 even reduced haloperidolinduced catalepsy and prevented olanzapine from increasing body weight and fat accumulation. Finally, TAAR1 activation promotes vigilance in rats and shows pro-cognitive and antidepressant-like properties in rodent and primate models. These data suggest that TAAR1 agonists may provide a novel and differentiated treatment of schizophrenia as compared with current medication standards: TAAR1 agonists may improve not only the positive symptoms but also the negative symptoms and cognitive deficits, without causing adverse effects such as motor impairments or weight gain.
INTRODUCTION
Schizophrenia is a chronic debilitating disorder affecting B1% of the population whose pathophysiological mechanisms remain poorly understood. 1--3 Aspects of schizophrenia are usually categorized into positive, negative and cognitive symptoms. The positive (or psychotic) symptoms include hallucinations, delusions and thought disorganization that are caused by an excess of dopamine (DA) in the mesolimbic system. 4--6 These symptoms are blocked by antipsychotic medication through inhibition of the DA D 2 receptors. 3, 7, 8 In contrast, the negative symptoms (flattened affect and emotions, anhedonia), and cognitive symptoms (impaired executive functions, attention and memory), which are believed to result from a DA deficiency in the prefrontal cortex (PFC), 4--6,8 are poorly responsive to current treatments. In addition to this limited therapeutic efficacy, current antipsychotic treatments produce undesirable side effects that compromise compliance with long-term treatment and quality of life. 9--11 The first generation of drugs (typical antipsychotics, or neuroleptics) causes loss of emotional responsiveness and extrapyramidal motor disorders, such as tardive dyskinesia or dystonia, whereas the second generation (atypical antipsychotics) engenders weight gain, diabetes and increased cardiometabolic risks. 9, 11, 12 As the cognitive and negative symptoms have a major impact on longterm morbidity, 1, 13 there is a critical need for treatments that combine the efficacy of current antipsychotics on the positive symptoms with improved effect on the negative and cognitive symptoms, without causing motor or metabolic side effects. 1, 7, 13 The development of antipsychotic drugs has typically focused on the DA D 2 receptor as a target, considering treatment of psychotic symptoms as the primary outcome. 7, 13 Engineering superior treatments will require addressing new biological targets, along with considering not only psychosis but also the mood and cognitive aspects of the disease when evaluating efficacy. 1,13--15 Although the DA hypothesis of schizophrenia, which postulates a DA dysfunction, remains an important premise for the disorder, several lines of evidence suggest a more complex picture in which the neurotransmission of other monoamines, glutamate and gammaaminobutyric acid, is also dysregulated 5 . Discovered in 2001, 16 ,17 the trace amine-associated receptor 1 (TAAR1) has been demonstrated to be an important modulator of the dopaminergic and serotonergic systems 18--22 and potentially also of glutamatergic activity. 18 TAAR1 is a G protein-coupled receptor that responds to so-called trace amines (TAs), a subgroup of biogenic amines previously denoted as false neurotransmitters. 16,17,19--21,23 TAs such as b-phenylethylamine (PEA), p-tyramine (pTyr) or tryptamine are endogenous metabolites of amino acids with structural similarity to biogenic amines. 22, 24 Although they are only found at low concentration in the brain, abnormal levels of TAs have long been associated with various neuropathological disorders, including schizophrenia, major depression and Parkinson's disease. 19,22--26 In schizophrenic patients, urinary and plasma PEA levels are increased, suggesting a role in the etiology of the disease. 26--29 Similar dysregulations of pTyr and tryptamine have also been reported. 25, 30, 31 The TAAR1 gene maps to locus 6q23, a region frequently associated with schizophrenia and bipolar disorder. 24, 26 In the mouse brain, Taar1 is expressed throughout the limbic and monoaminergic systems, including the ventral tegmental area (VTA) and dorsal raphe nucleus (DRN). 32 Mice lacking Taar1 (Taar1 À/À mice) have no overt phenotype, however, they are hypersensitive to amphetamine, showing enhanced locomotion and striatal release of DA, noradrenaline and serotonin (5-hydroxytryptamine (5-HT)) following an acute challenge. 32, 33 Furthermore, the spontaneous firing rate of DA and 5-HT neurons in the VTA and DRN, respectively, is augmented in Taar1 À/À mice, and only in wild-type mice does pTyr decrease this firing rate. 18, 32, 34 These observations indicate that TAAR1 is an important modulator of monoaminergic neurotransmission and suggest therapeutic value in the context of neuropsychiatric disorders.
Recently, engineering of two novel, selective and potent ligands of mouse TAAR1, an antagonist (EPPTB or RO5212773) 34, 35 and an agonist (RO5166017), 18 has reinforced the therapeutic potential of TAAR1. Use of these ligands in vitro has revealed that TAAR1 interacts functionally with the D 2 and 5-HT 1A receptors in the VTA DA and DRN 5-HT neurons, respectively, to modify their pharmacological properties. 18, 34, 36 In vivo, TAAR1 agonism produced anxiolytic and antipsychotic-like effects in several mouse models. 18 Notably, similar to the antipsychotic drug olanzapine, RO5166017 reduces the DA-dependent hyperlocomotion triggered either by cocaine or genetic deletion of the DA transporter, as well as hyperactivity induced by an N-methyl D-aspartate (NMDA) antagonist. 18 To further examine the therapeutic potential of TAAR1, we designed two agonists with high potency and selectivity at mouse, as well as rat, Cynomolgus monkey (Macaca fascicularis) and human TAAR1. These new compounds, RO5256390 (full agonist) and RO5263397 (partial agonist), show distinct pharmacological signatures and display a promising profile in a range of paradigms and disease models in rodents and primates, suggesting not only antipsychotic-like properties but also pro-cognitive and antidepressant potential.
MATERIALS AND METHODS Animals
Animal experiments at Roche (Basel, Switzerland) complied with the Swiss Federal and Cantonal laws on animal research and AAALAC regulations and received prior approval by the Cantonal Veterinary Office. Experiments with monkeys performed at Roche (Palo Alto, CA, USA) conformed with the local Institutional Animal Care and Use Committee guidelines and AAALAC regulations. Sleep studies at SRI International were approved by SRI's Institutional Animal Care and Use Committee and were in accordance with the NIH guidelines. Details on animal provenance and housing are provided in Supplementary Methods.
Drugs
All compounds were obtained from Sigma except where specified. (3R,4R)-3-amino-1-hydroxy-4-methyl-2-pyrrolidinone (L-687,414), olanzapine, RO5256390, RO5263397, EPPTB (RO5212773), [ 
Pharmacological studies
The cAMP and radioligand-binding assays were performed as described, (monkey and human TAAR1) as TAAR1 radioligands at a concentration equal to K d .
Electrophysiological recordings
Electrophysiological recordings in Xenopus oocytes expressing mouse TAAR1 and human K ir 3.1/3.2 were performed as reported. 18, 34 Visual whole-cell current clamp in brain slices were used to record firing activity of VTA DA neurons and 5-HT DRN neurons as published previously. 18, 34 Horizontal slices (250 mm thick) were prepared from adult (3--6 months of age) wild-type and Taar1 À/À mice. All cells used for the statistical analysis displayed a stable firing activity for at least 30 min.
Selectivity screen RO5256390 and RO5263397 were tested in a selectivity screen at CEREP (Paris, France) as documented in Supplementary Methods.
Pharmacokinetic studies
Pharmacokinetic analyses were performed as described in Supplementary Methods.
Measurement of locomotor activity (LMA) in mice
LMA was evaluated as the number of horizontal beam breaks (horizontal activity) over 30 min as described, 18,32 except where specified. Psychostimulants were dissolved in saline (0.9% NaCl þ 0.3% Tween 80). RO5256390 and RO5263397 were dissolved in vehicle (H 2 O þ 0.3% Tween 80) and administered orally, except where specified.
Cocaine experiments. C57BL/6J mice (n ¼ 8 per group) were administered with vehicle, RO5256390 (0.3--3 mg kg À1 ) or RO5263397 (0.3--3 mg kg À1 ), placed into the activity monitor chamber for 30 min (habituation period), injected intraperitoneally with cocaine (20 mg kg À1 ) and returned to the recording chamber for LMA monitoring (recording period). Cocaine experiments in association with olanzapine. C57BL/6J mice (n ¼ 8 per group) were administered with RO5256390 (0.1 mg kg À1 ) or RO5263397 (0.3 mg kg À1 ) 30 min before receiving vehicle or olanzapine (0.3--1 mg kg À1 orally), and were placed into the activity monitor chamber for 30 min (habituation period), injected with cocaine (20 mg kg À1 , intraperitoneally) and returned to the recording chamber for LMA monitoring (recording period). The choice of doses for the TAAR1 compounds was based on prior dose-response studies with compounds from which a threshold dose for activity was selected for the combination study.
Phencyclidine
L-687,414 experiments in association with olanzapine. NMRI mice (n ¼ 8 per group) were administered with RO5263397 (0.001 mg kg À1 )
30 min before receiving vehicle or olanzapine (0.02--0.1 mg kg À1 orally). After 15 min, the animals were injected with L-687,414 (50 mg kg À1 , subcutaneously), and were then placed into the activity monitor chamber for 15 min (habituation) before LMA was recorded for 60 min.
Pharmacological magnetic resonance imaging (phMRI)
Adult male Sprague-Dawley rats (250--300 g; n ¼ 8--9 per group) were dosed orally with either vehicle (0.9% NaCl þ 0.3% Tween 80) or olanzapine ) or RO5263397 plus olanzapine in study 2. Then body fat mass and lean mass contents were measured again and compared with the pretreatment values. In addition, food intake and body weight (BW) were assessed daily, and the cumulative weight gain and food intake were determined.
Haloperidol-induced catalepsy
Haloperidol-induced catalepsy tests were performed as described in Supplementary Methods.
Object retrieval
The object retrieval paradigm was performed as reported previously 38, 39 with minor variations. Briefly, 12 adult male Cynomolgus macaques were presented with a clear acrylic box ( Attentional set-shifting
The attentional set-shifting task was performed with adult male LongEvans rats (225--275 g) as reported previously 40, 41 and described in Supplementary Methods. All animals were treated subchronically with saline or PCP (5 mg kg À1 bis in die (twice daily), intraperitoneally) for 7 days, and experienced a washout period of 7 days before beginning habituation and training to the set-shifting procedure. On the day of testing, rats were given vehicle (H 2 O þ 0.3% Tween 80) or RO5256390 (1--10 Differential reinforcement of low-rate behavior Adult male Cynomolgus monkeys (5--9 kg; n ¼ 6 per group) were trained to press a lever for food under a fixed ratio one schedule until they were able to earn 100 pellets during a 1-h training session. Monkeys were then introduced to the differential reinforcement of low-rate behavior schedule where they were presented with a titrated delay period (5, 10, 30, 60, 100, 120, 160, 180 and 240 s) in which a premature response would not elicit a food reward and the interval was reset. Training continued until the animals showed stable performance of two to six reinforcers during the 1-h session under vehicle conditions. For RO5256390, animals received vehicle (20% 1-methyl-2-pyrrolidinone in citrate buffer) or RO5256390 (0. Electroencephalography (EEG), core body temperature (T b ) and LMA telemetric studies Data recording and analysis were as reported. 42 Three groups of eight male Sprague-Dawley rats (300 ± 25 g) were implanted with recording devices for telemetric recordings of EEG, electromyography, T b and LMA. Animals were acclimated to the handling procedures and were given two separate 1 ml doses of vehicle p.o., one 7 days and the other 3 days before the first experimental day. Three studies were performed. For each study, a repeated measures design was used in which each rat received five separate oral dosings (2 ml kg À1 ). In a first study, the dosings consisted of RO5256390 at three concentrations (1--10 mg kg À1 ), a vehicle control (H 2 O þ 0.3% Tween 80) and zolpidem (30 mg kg À1 ) during the middle of the active (dark) period at Zeitgeber time 18 (Zeitgeber time 0 defined as light onset). In a separate experiment, rats received RO5263397 at three high concentrations (3--30 mg kg À1 ), a vehicle control (H 2 O þ 0.3% Tween 80) and caffeine (10 mg kg À1 ) (RO5263397 study 1). In a third study, rats received RO5263397 at three low concentrations (0.3--3 mg kg À1 ), a vehicle control (H 2 O þ 0.3% Tween 80) and caffeine (10 mg kg À1 ) (RO5263397 study 2). In studies with RO5263397, dosing occurred during the middle of the resting (light) period at Zeitgeber time 7. In all studies, the animals were then recorded for 6 h. Subsequent data analysis was performed as described in Supplementary Methods.
Statistical analyses
Data represent the mean ± s.e.m. A P-value of 0.05 was accepted as statistically significant. Electrophysiological data were analyzed with the Kolmogorov--Smirnoff test. Rodent behavioral data were analyzed with Student's t-test, Mann--Whitney test, one-way analysis of variance (ANOVA), Kruskal--Wallis test or one-way repeated measures ANOVA, followed by Dunnett test, as appropriate. Catalepsy data were analyzed by Fisher's exact test (RO5256390) or Mann--Whitney and Kruskall--Wallis tests followed by post-hoc Mann--Whitney tests. Monkey data were analyzed with one-way repeated measures ANOVA or non-parametric repeated measures ANOVA, followed by Dunnett test. The phMRI data were analyzed as detailed in Supplementary Methods. BW changes were analyzed by two-way ANOVA with post-hoc interaction contrasts comparing the linear time trend of each group against that of the vehicle and olanzapine control groups followed by single comparisons with t-tests at each time point. Food intake and body composition data were analyzed with one-way ANOVA followed by Dunnett test. EEG data were analyzed using one-or two-way repeated measures ANOVA followed by paired t-tests. Table 1 ) were engineered by medicinal chemistry using the same strategy as for RO5166017. 18 Both compounds exhibit high affinity at mouse, rat, Cynomolgus monkey and human TAAR1 stably expressed in HEK293 cells, where they potently activated cAMP production in all species (Table 1) . In Xenopus oocytes co-expressing mouse TAAR1 with human K ir 3 channels, both molecules evoked an inward current with potency comparable to that observed in the cAMP assays (Table 1) . However, the two compounds activated TAAR1 with different efficacies; while maximal cAMP levels reached by RO5256390 stimulation (79--107%) were comparable to that achieved by PEA (set as 100%), cAMP levels triggered by RO5263397 were lower (59--85%), suggesting partial agonism. The difference between the two compounds became even more evident when tested on brain slices using patch-clamp recordings (Table 1 ; Supplementary Figure 1 ). RO5256390 behaved like the TAAR1 agonists pTyr and RO5166017, 18 decreasing the firing frequency of VTA DA and DRN 5-HT neurons, whereas RO5263397 increased their firing rate, similar to the TAAR1 antagonist EPPTB, 34 supporting a TAAR1 partial agonist profile for RO5263397. Importantly, neither RO5256390 nor RO5263397 altered the firing rate of VTA DA and DRN 5-HT neurons in slices from Taar1 À/À mice (Supplementary Figure 1) , demonstrating TAAR1-specific effects in the wild type. Of note, while the antagonistic efficacy of RO5256390 on the electrophysiological recordings was similar to the agonistic potency measured in the cAMP assays, the agonistic measures for the TAAR1 partial agonist RO5263397 differed (Table 1) . One explanation may be the relative inefficiency of the partial agonist RO5263397 to overcome TAAR1 constitutive activity or tonic activation by ambient levels of agonist(s) in the preparation.
Both compounds showed high selectivity for TAAR1, as determined from radioligand binding assays (CEREP) using 155 target proteins (Supplementary Table 1 ). For targets where significant binding was seen at 3 mM, additional K i determinations revealed a low affinity for all targets tested (X66-fold selectivity for mouse TAAR1 K i versus target K i ), including members of the monoaminergic system. The only exception was the imidazoline I 2 receptor for which RO5263397 showed a selectivity ratio (K i /K i ) of 13-fold in favor of mouse TAAR1. In addition, neither RO5256390 nor RO5263397 at concentrations up to 30 mM elicited cAMP production in HEK293 cells stably expressing mouse TAAR4 (Supplementary Table 1 ), the only other TAAR family member activated by TAs. 43 Finally, pharmacokinetic analyses in mouse, rat and Cynomolgus monkey revealed favorable in vivo properties for both compounds (Table 2) . Thus, RO5256390 and RO5263397 are highly potent and selective TAAR1 agonists that are well suited for in vivo investigations in rodents and primates. Importantly, they display distinct intrinsic efficacies at TAAR1, RO5256390 being a full agonist and RO5263397 a partial agonist.
TAAR1 agonism produces antipsychotic-like effects and potentiates the antipsychotic properties of olanzapine Recently, we demonstrated that RO5166017, a TAAR1 agonist with high efficacy and selectivity at mouse TAAR1, exhibits antipsychotic-like properties in mice. 18 Accordingly, we asked whether RO5256390 and RO5263397 possess comparable properties. Similar to RO5166017 and to olanzapine, 18 both compounds fully antagonized the locomotor-stimulating effects of cocaine, an indirect DA agonist that blocks the DA transporter ( Figure 1a ). In addition, both RO5256390 and RO5263397 dose-dependently inhibited hyperlocomotion induced by two types of noncompetitive NMDA receptor blockers, PCP and L-687,414 ( Figures  1b and c) . 44, 45 In these paradigms, the potencies of the new TAAR1 agonists were remarkably high, with a full effect of RO5263397 on L-687,414-induced hyperlocomotion observed starting at 0.003 mg kg À1 (Figure 1c ). These data confirm previous observations with RO5166017 18 and support the antipsychotic-like properties of TAAR1 agonism. Interestingly, we further observed that TAAR1 agonists significantly potentiated the effect of olanzapine in blocking either cocaine-or L-687,414-induced hyperlocomotion (Figures 1d--f) . Similar results were obtained with RO5263397 in potentiating the effects of another antipsychotic drug, risperidone, on blocking cocaine-induced hyperlocomotion (Supple- The brain activity pattern induced by TAAR1 agonism is similar but not identical to that of olanzapine As TAAR1 agonists produced antipsychotic-like actions similar to those of olanzapine in behavioral paradigms, we imaged and compared their effects on brain activity in living animals. For this, the effects of olanzapine (6 mg kg À1 p.o.) and different doses of RO5256390 or RO5263397 (1--30 mg kg À1 , p.o.) administered to rats were assessed by phMRI based on continuous arterial spin labeling, as described previously. 46, 47 Continuous arterial spin labeling-phMRI provides a measure of regional blood perfusion (that is, diffusion of water from the capillary bed into the neuronal tissue), which in turn is taken as a surrogate measure of local neuronal activity levels. Compared with vehicle-treated animals, the three compounds altered brain perfusion in a comparable manner (Figures 2a and b; Supplementary Figure 3a) , with a general tendency for increased perfusion in cortico-limbic areas (for example, the medial PFC and temporal cortex) and decreased perfusion in more ventral, subcortical structures, such as the VTA, substantia nigra, raphe nuclei, shell of the nucleus accumbens and entorhinal/piriform cortex (Supplementary Table 2 ). The magnitude of these changes differed with treatment and doses, but was generally milder with TAAR1 agonists than with olanzapine, especially in the medial PFC and raphe nuclei ( Table 2 ). In contrast, six structures showed different responses to olanzapine and TAAR1 agonists (Figure 2c; Supplementary Figure 3b) . Perfusion in the locus coeruleus, thalamus and core of the nucleus accumbens decreased after olanzapine, but remained unchanged after TAAR1 agonists. Similarly, olanzapine and RO5256390 did not alter perfusion in the striatum, whereas it was significantly augmented by RO5263397 at high dose. Interestingly, TAAR1 agonists did not significantly affect perfusion in the locus coeruleus (Supplementary Figure 3b ), where TAAR1 is neither expressed nor functional. 18, 32 Finally, determination of the pattern match coefficient (Figure 2d ) confirmed that TAAR1 agonists and the atypical antipsychotic olanzapine alter neural activity in a similar, but not identical manner. Taken together, these imaging data further support the antipsychotic potential of RO5256390 and RO5263397 and its differentiation versus olanzapine, a representative of current antipsychotic medication.
TAAR1 agonism does not increase BW and protects from olanzapine-induced BW gain A major side effect of antipsychotic medication is weight gain, which increases the risk of cardiovascular adverse events and diabetes, reduces the quality of life and causes treatment discontinuation. 9, 10, 48 Taar1 expression has been detected by reverse transcription-PCR in several peripheral organs, 16,17,49--51 including the pancreas and gastrointestinal tract where TAAR1 activation might alter metabolic functions and BW regulation. Using the Taar1 À/À mouse line in which Taar1 has been replaced by the LacZ reporter gene, 32 we confirmed histologically the presence of Taar1 expression in several peripheral organs (Supplementary Table 3 ). In agreement with the previous reports, 49--51 staining of b-galactosidase activity showed that RO5256390 showed low to moderate oral bioavailability, which was improved with i.p. and i.m. administration in the mouse and monkey, respectively, moderate to high volume of distribution at steady state, an elimination half-life of several hours and a high brain/plasma concentration ratio (11 Â more in the brain). RO5263397 showed moderate to high oral bioavailability, moderate to high volume of distribution at steady state, half-life of several hours and a high protein unbound fraction. Mouse parameters were derived from mean plasma concentrations for n ¼ 2 animals per time point. Rat and monkey parameters were derived from mean plasma concentrations for n ¼ 2 (rat) and n ¼ 3 (monkey) animals per dose route.
TAAR1 (Figures 3a--c) . No b-galactosidase activity was detected in tissues of control mice (Supplementary Figure 4) . Co-staining in the pancreas demonstrated that Taar1 is expressed by insulin-secreting b cells, but not by glucagon-secreting a cells (Figures 3d and e; Supplementary Figures 5 and 6 ). These histological data show that Taar1 is expressed by peripheral organs associated with food absorption and control of glucose metabolism. Although the function of TAAR1 in these organs remains to be determined, it suggests a putative role for TAAR1 in the regulation of metabolic functions beside central functions.
As TAAR1 agonists exhibit antipsychotic-like properties and display a brain activity profile reminiscent of olanzapine, and especially considering the peripheral expression pattern of the receptor, we addressed the question whether TAAR1 agonism may alter BW like antipsychotic drugs. In rats, daily treatment with RO5263397 for 2 weeks did not cause BW gain, as compared with vehicle ( Figure 3f) . Instead, BW stabilized and did not increase as in control rats, presumably due to the observed reduction of food intake (Supplementary Figure 7a) . This translated into slight, but nonsignificant reductions of the lean and fat masses (Figure 3f ; 48 RO5263397 does not increase BW in rat but rather tends to decrease it.
Atypical antipsychotics are considered partly more effective than conventional neuroleptics on the negative and cognitive symptoms. 13, 52 However, they lead to greater weight gain and metabolic disturbances which, eventually, preclude improvement of the benefit-to-risk ratio. 9, 11, 12 Among these, clozapine and olanzapine have the greatest propensity for inducing weight gain. 9 As we determined earlier that TAAR1 agonism potentiates the antipsychotic action of olanzapine, we examined whether it would also modulate the effects of olanzapine on BW. Rats treated daily with olanzapine (2 mg kg À1 , p.o.) experienced large increases of BW and fat mass as compared with vehicle-treated animals (Figure 3g ). However, co-treatment with a low dose of RO5263397 (1 mg kg À1 , p.o.) prevented olanzapine from increasing both BW and fat accumulation (Figure 3g ), whereas the same dose of RO5263397 did not alter significantly BW gain nor body fat mass when given alone. Similarly, RO5263397 also blocked the olanzapine-induced increase of food intake (Supplementary Figure  7b) . Overall, this experiment reveals that the TAAR1 partial agonist RO5263397 has a remarkable profile in concomitantly potentiating the antipsychotic effects of olanzapine while minimizing its metabolic-related adverse effects. TAAR1 agonists reduce neuroleptic-induced catalepsy Extrapyramidal symptoms are major side effects of typical antipsychotics caused by DA neurotransmission blockade in the striatum. 53 In animals, neuroleptics (for example, haloperidol) induce comparable motor side effects defined as catalepsy, a prolonged state of fixed posture and muscular rigidity. 54 In contrast, neither RO5256390 nor RO5263397 produced muscular stiffness or any other signs of catalepsy. Moreover, because TAAR1 alters DA and 5-HT neurotransmission, which modulates extrapyramidal symptoms, 55 we examined whether TAAR1 agonists affect the cataleptic state caused by haloperidol. Rats injected with haloperidol experienced catalepsy, which was partly prevented by the partial agonist RO5263397 at all doses tested (Supplementary Figure 8) . In contrast, the full agonist RO5256390 was less effective, catalepsy being reduced significantly by dose 0.3 mg kg À1 only. Thus, partial activation of TAAR1 seems advantageous over full agonism for reducing neuroleptic-induced extrapyramidal side effects. TAAR1 agonists enhance cognitive performance As TAAR1 modulates monoaminergic functions, 18, 19, 21, 32, 34 which regulate cognitive processes and mood states, we explored whether TAAR1 agonists may also address the cognitive and negative symptoms of schizophrenia, for which available treatments have insufficient efficacy.
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The effects of RO5256390 and RO5263397 on cognitive performance were first assessed in monkey using the object retrieval paradigm, a test of attention and response inhibition mediated by the PFC. 39, 56 Cynomolgus macaques were presented with a transparent acrylic box with one open side baited with a food treat, and monkeys made attempts to obtain the treat in 'easy' (treat close to the open side) and 'difficult' (treat deep within box) trials. In the difficult trials, monkeys obtain the treat on the first attempt B50% of the time. Drugs with cognition-enhancing properties improve accuracy. 38 Similarly, both TAAR1 agonists enhanced performance during difficult trials (Figure 4a) , with 66% and 67% of correct responses obtained with minimally effective doses of RO5256390 at 3 mg kg À1 intramuscularly and RO5263397 at 1 mg kg À1 p.o., respectively. The pro-cognitive effects of TAAR1 activation were also assessed in rat using the attentional set-shifting paradigm, a rodent analog of the Wisconsin Card Sorting task in human. 40, 41 Both tasks capture response inhibition, cognitive flexibility and attention (that is, executive function), behavioral domains subserved by the frontal cortex and often impaired in schizophrenia. 4, 15 In rat, subchronic administration of NMDA receptor antagonists such as PCP produces long-lasting neurochemical changes and performance impairments in set-shifting, similar to the cognitive impairments observed in schizophrenia. 40, 41 Those deficits can be reversed by cognitive enhancers, 40 ,41,57 but generally not by antipsychotic drugs, including olanzapine or clozapine. 41 Here, animals were treated with PCP for 7 days, and were trained after another 7-day washout period to discriminate between various tactile and odor cues (that is, set-shifting). Consistent with previous reports, 40, 41, 57 PCP induced a selective impairment in extradimensional attentional set-shifting (Figure 4b ) without affecting discrimination or reversal learning (data not shown). This indicates that PCP treatment specifically alters attention shifting without causing a generalized learning impairment. 57 Importantly, acute administration of RO5256390 before testing reversed the PCP-induced deficit in extradimensional attentional set-shifting performance at doses 1 and 3 mg kg À1 (Figure 4b ).
Taken together, these results demonstrate that TAAR1 activation promotes executive function in primates and rodents, suggesting potential benefits for the cognitive deficits in schizophrenia.
TAAR1 agonism produces antidepressant-like effects Given the modulating role of TAAR1 on the neurotransmission of monoamines, 18, 19, 21, 32, 34 which has a central role in controlling mood states, we next addressed the effects of RO5256390 and RO5263397 on depression-related behaviors. TAAR1 agonists were first evaluated in rat using the forced-swim test, the most widely used preclinical tool for assessing antidepressant activity. 58 In this paradigm, the partial agonist RO5263397 dose-dependently reduced immobility time compared with vehicle (Figure 5a) , as opposed to the full agonist RO5256390, which did not significantly affect immobility time at any of the doses investigated. This suggests potential antidepressant-like properties for the TAAR1 agonists with lower intrinsic efficacy.
Then, TAAR1 agonists were assessed in monkey using the differential reinforcement of low-rate behavior paradigm, a form of schedule-controlled behavior in which subjects are reinforced for withholding a response over a specified unsignaled delay interval. 59 In this paradigm, antidepressant drugs augment the number of reinforcers obtained and reduce response rates. 59 In Cynomolgus macaques, RO5256390 and RO5263397 produced response profiles reminiscent of antidepressant drugs (Figure 5b ). Both compounds increased significantly the number of reinforcers obtained, while RO5256390 further lowered the response rate and lengthened the inter-response time. Taken together, these data show that TAAR1 activation has antidepressant potential and may ameliorate negative symptomatology in disorders such as major depression or schizophrenia.
The TAAR1 partial agonist RO5263397 increases wakefulness As TAAR1 modulates monoaminergic activity, a critical component in the regulation of vigilance states, 60 we investigated whether RO5256390 and RO5263397 alter sleep--wake activities, as determined by telemetric recordings of the EEG, electromyogram, T b and LMA in Sprague-Dawley rats. The effects of the full agonist RO5256390 were evaluated after administration in the middle of the dark (active) period and compared with the standard hypnotic drug zolpidem. RO5256390 did not affect the amount of wakefulness, non-rapid eye movement sleep (NREM) and REM over the 6 h subsequent to administration (Supplementary Figures  9a--c) , nor did it modify the latency to sleep and the REM:NREM ratio (Supplementary Figures 9d--f) . The measures of sleep--wake consolidation, NREM delta power, T b and LMA were not significantly altered either (data not shown). In marked contrast, zolpidem produced the expected hypnotic effects (Supplementary Figure 9 ) together with large reductions of LMA and T b (data not shown). These data indicate that TAAR1 activation with RO5256390 does not significantly alter the sleep--wake activities, at least when given during the active phase.
Accordingly, the effects of the partial agonist RO5263397 were then evaluated after administration in the middle of the light period (the normal rest period for nocturnal rodents) in comparison with the standard wake-promoting compound, caffeine. At this time of the day, RO5263397 (3--30 mg kg À1 , p.o.) strongly promoted wakefulness at the expense of sleep (Supplementary Note 1; Supplementary Figures 10--12) . This observation was confirmed in a subsequent experiment with lower doses (0.3--3 mg kg À1 , p.o.) intended to determine the dose-dependency of the wake-promoting effects (Figure 6 ; Supplementary Note 2; Supplementary Figures 11 and 13) . Together, these two experiments with RO5263397 point to a robust and dose-dependent increase of wakefulness over the 6 h subsequent to administration, while NREM and REM were reduced. RO5263397 increased the latency to REM, but not to NREM, and greatly reduced the REM:NREM ratio ( Figure 6; Supplementary Figure 10) . Caffeine promoted vigilance as expected with additional characteristic increase in LMA and T b that RO5263397 did not produce (Supplementary Figure 14) . Collectively, these results show that TAAR1 partial activation by RO5263397 promotes vigilance when given during the light phase.
DISCUSSION
Current medications for schizophrenia and related disorders are still unsatisfactory. 1 Although antipsychotic drugs effectively address psychotic symptoms, they show poor efficacy on negative and cognitive symptoms, in addition to being associated with severe motor, hormonal and metabolic side effects. 3, 9, 11, 53 Here, we provide compelling evidence that TAAR1 agonism could be used for the treatment of conditions such as schizophrenia, bipolar disorder or major depression. Using the novel agonists RO5256390 and RO5263397, we reveal that TAAR1 activity benefits a wide range of psychobiological domains, highlighting the importance of TAAR1 in fine tuning 'normal' brain functioning. RO5256390 and RO5263397 are TAAR1 agonists with distinct and improved pharmacological properties Here, we report on two new potent and selective agonists of TAAR1 with improved pharmacological profiles and optimized pharmacokinetic properties in rat, Cynomolgus monkey and, most importantly, human, compared with RO5166017, a recently characterized mouse TAAR1 agonist.
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RO5256390 and RO5263397 exhibit good selectivity for TAAR1 over a large panel of targets, including monoamine receptors and transporters. The only exceptions are, for RO5263397, the imidazoline I 2 receptor, and for RO5256390, the 5-HT 2B receptor, and to a lesser extent the 5-HT 2A , delta 2 opioid, imidazoline I 1 and muscarinic M 3 receptors. Interactions with imidazoline receptors are not thought to be essential for the biological activity of TAAR1 agonists as both RO5256390 and RO5263397 failed to alter the firing rate of VTA DA and DRN 5-HT neurons in brain slices from Taar1 À/À mice, despite the presence of binding sites for I 2 in the VTA and for both I 1 and I 2 in the DRN. 61 Along these lines, the firing frequency of DRN 5-HT neurons is reduced by harmane, a putative endogenous ligand of imidazoline-binding sites, 61 whereas RO5256390 and RO5263397 failed to produce such an effect in Taar1 À/À mice. Concerning the other receptors hit by RO5256390, they are unlikely to contribute significantly to its biological activity as RO5263397 produced similar effects without having significant affinity for those targets.
A major pharmacological difference between RO5256390 and RO5263397 lies in their respective degree of intrinsic efficacy at TAAR1. Whereas RO5256390 triggers maximal receptor activation similar to pTyr, RO5263397 produces only partial activation. Both agonists are similarly active in a number of experimental conditions but, in some paradigms, differences were observed (for example, patch-clamp, forced-swim test, EEG and haloperidol-induced catalepsy). In patch-clamp recordings, TAAR1 full activation by RO5256390 attenuates neuronal firing in the VTA and DRN, similar to pTyr or the full agonist RO5166017. 18 In contrast, TAAR1 partial activation by RO5263397 augments the firing frequency, as seen with the TAAR1 antagonist EPPTB or in brain slices of Taar1 À/À mice. 34 Whether and where such differential effects occur in an intact brain with its large and complex networks remain to be determined. Although the in vivo effects of an agonist are easily predicted, those of a partial agonist are more challenging to anticipate, as its effects depend on the relative degree of receptor activation, which can vary according to the brain area considered, the presence of endogenous agonist(s), the degree of TAAR1 constitutive activity, as well as the pathophysiological status. In vitro, previous observations suggested that TAAR1 is constitutively active and/or tonically activated by endogenous agonist(s), 18 ,34 a situation where partial agonism results in antagonist-like effects on firing activity. In vivo, TAAR1 can be activated not only by endogenous TAs and related amine metabolites (for example, synephrines) but also by DA and 5-HT that are partial agonists at TAAR1. 17, 43 Accordingly, 
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TAAR1 agonism to treat the positive symptoms of schizophrenia Both RO5256390 and RO5263397 exhibit antipsychotic-like properties in rodent tests. Both compounds reduce hyperactivity in mice challenged with cocaine, a psychostimulant that increases extrasynaptic DA, or with NMDA receptor blockers, such as PCP and L-687,414. Along these lines, the TAAR1 agonist RO5166017 also inhibits locomotion in spontaneously hyperactive DA transporter knockout mice, a genetic model of hyperdopaminergia. 18, 62 Thus, the antipsychotic potential of TAAR1 agonism is supported by the fact that various TAAR1 agonists with slightly different pharmacological profiles all show potent activity in pharmacological and genetic models of schizophrenia. Interestingly, TAAR1 agonists are effective both in models based on either increased DA activity or reduced glutamatergic NMDA activity, 62 similar to typical and atypical antipsychotic drugs. In addition to showing antipsychotic-like effects on their own, RO5256390 and RO5263397 also add to the effects of suboptimal doses of olanzapine on blocking cocaine-or L-687,414-induced hyperlocomotion. Assuming that similar synergies occur in patients, the doses of olanzapine could be reduced to minimize its side effects without altering therapeutic efficacy.
Importantly, TAAR1 agonists are unlikely to cause extrapyramidal side effects as we did not observe any signs of motor rigidity or dysfunctions following treatments with RO5256390 or RO5263397, in contrast to typical antipsychotic drugs. On the contrary, RO5263397 even partially prevented haloperidol-induced catalepsy in rat, suggesting that TAAR1 partial activation may mitigate extrapyramidal side effects caused by neuroleptics.
This finding is in agreement with a recent report by Espinoza et al., 36 who found that haloperidol-induced catalepsy and striatal c-Fos expression was significantly reduced in mice lacking TAAR1. This suggests that RO5263397 effects are more likely due to its antagonistic properties, implying TAAR1 activation by endogenous TAs and/or constitutive receptor activation. How TAAR1 antagonism relieves catalepsy induced by D 2 blockade is unclear, but may involve TAAR1 modulatory effects on monoaminergic neurotransmission. 5, 18, 21, 55 Interestingly, neuroleptics like haloperidol were shown to enhance the activity of the aromatic L-aminoacid decarboxylase followed by an increased dopaminergic activity due to elevated PEA and possibly DA synthesis. 63, 64 Based on our results the TAAR1 partial agonist RO5263397 may inhibit this effect induced by haloperidol.
In line with the behavioral observations, the phMRI data show that RO5256390 and RO5263397 produce brain activity signatures reminiscent of atypical antipsychotics such as olanzapine or aripiprazole. 65 This contrasts with neuronal activity patterns observed in schizophrenic patients and animal models. Imaging studies in schizophrenic patients have consistently demonstrated dysfunctions of the fronto--temporal cortical areas, whereas studies in rats using either neurodevelopmental or pharmacological (PCP or amphetamine treatments) models of schizophrenia have revealed abnormally decreased activity in the temporal and PFCs associated with increased activity of the entorhinal/piriform cortex and shell of the nucleus accumbens. 46, 47 Altogether, these data suggest that in patients TAAR1 agonists have the potential to normalize deficient brain activity and generate antipsychotic effects. Interestingly, in some brain areas, such as the thalamus or the locus coeruleus, TAAR1 agonists and olanzapine altered brain activity in a different manner, suggesting that in patients differential effects may occur for certain disease symptoms.
Of note, some effects of atypical antipsychotics might occur via indirect action on TAAR1. In a recent study, Karmacharya et al.
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Figure 6. RO5263397 increases vigilance in rats. RO5263397 dose-dependently enhanced the cumulative time spent in wake (a) and decreased the cumulative times in non-REM (NREM) (b) and REM sleep (c) over the 6-h period following dosing in the middle of the resting phase (Zeitgeber time 6). RO5263397 did not alter significantly the latencies to NREM onset (d) and REM onset (e) and decreased the REM to NREM sleep ratio (f ). Similarly, the positive control caffeine (10 mg kg À1 , p.o.; CAF) enhanced wakefulness and the latencies to NREM and REM, while decreasing the time spent in NREM and REM and increasing the REM to NREM ratio. ***Po0.001, **Po0.01 and *Po0.05 versus vehicle (veh) (n ¼ 8 per group). Numbers on the X-axes represent oral doses of RO5263397 (mg kg À1 ). Data represent the mean ± s.e.m.
TAAR1: a promising target for schizophrenia therapy FG Revel et al demonstrated in mouse that TAAR1 is necessary for the enhancing effects of clozapine in the prepulse inhibition test, a paradigm that evaluates sensorimotor gating capacities. Deficits in prepulse inhibition are observed in schizophrenic patients and animal models indicative for schizophrenia, and antipsychotics improve prepulse inhibition performance. 67 This suggests that TAAR1 activation is disrupted in schizophrenia and that some antipsychotics may produce part of their therapeutic effects via indirect modulation of TAAR1 activity.
TAAR1 agonists have the potential to target the negative and cognitive symptoms of schizophrenia Although current antipsychotic medications are generally effective on the positive symptoms of schizophrenia, they show little effects on the cognitive and negative symptoms. 1, 7, 13 Novel treatments aim to target these life-long aspects that are key to the long-term morbidity and functional outcome. 1 The cognitive and negative symptoms are believed to result from hypofunctioning of the PFC, a structure that has an important role in executive functions and working memory. Several lines of evidence suggest that hypoactivity of the prefrontal DA system underlies the cognitive deficits. 4--6,8 Atypical drugs, such as clozapine and olanzapine, have small effects on cognitive function in patients 68 that have been associated to enhanced prefrontal DA levels and neuronal activation, contrasting with typical antipsychotics. 69, 70 Our phMRI results in rats are consistent with such observations by showing that olanzapine increases prefrontal and temporal perfusion levels. Similarly, TAAR1 agonists enhance brain activity in these areas, suggesting potential impact of TAAR1 activation on cognitive functions. This was substantiated by the demonstration of pro-cognitive effects of TAAR1 agonists in behavioral paradigms in monkeys and rodents. Indeed, both compounds enhanced performance of naive monkeys in the object retrieval task. In this test, performance is improved by cognition-enhancing drugs 38, 39 but is greatly diminished after PCP exposure, correlating with reduced prefrontal DA function. 56, 71 In addition, RO5256390 reversed PCPinduced impairments of rats in the attentional set-shifting task. Interestingly, RO5256390 shares this property with cognitiveenhancing drugs, 40 but not with antipsychotic drugs, including haloperidol, clozapine and olanzapine, which all fail to reverse the PCP-induced executive function deficits. 41 Taken together, these results reveal a role for TAAR1 in modulating executive functions. TAAR1 agonists show pro-cognitive effects, which, combined with their antipsychotic-like properties, may represent a new treatment option for schizophrenia.
In addition to the cognitive alterations, prefrontal DA deficits may also contribute to the negative symptomatology. According to the phMRI data, RO5256390 and RO5263397 increased neural activity in prefrontal areas, suggesting that TAAR1 agonists may have beneficial effects on negative symptoms. RO5263397, but not RO5256390, exhibited antidepressantlike effects in the forced-swim test in rats, while both compounds showed a profile reminiscent of antidepressant drugs 59 when evaluated in primates using the differential reinforcement of lowrate behavior paradigm. Drugs from other therapeutic classes are usually devoid of such effects, although mixed results have been reported for antipsychotics, including haloperidol and clozapine.
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Of note, such studies were performed in rats, precluding direct comparison with our results in primates. Taken together, these data with RO5256390 and RO5263397 identify antidepressant-like effects of TAAR1 activation and suggest a new therapeutic option not only for the negative symptoms of schizophrenia, but potentially also for pathologies associated with depressive symptoms, such as major depression, bipolar disorders or Parkinson's disease.
A metabolic role for TAAR1: protection from olanzapine-induced BW gain In contrast to most antipsychotics, in particular those of the atypical class, 9, 11, 12 RO5263397 produces antipsychotic-like effects without increasing BW and fat mass in rats, and additionally protects against olanzapine-induced BW and fat mass gains. To our knowledge, this is the first compound that associates antipsychotic-like features with protection from atypical antipsychotic-induced BW gain. Thus, association of RO5263397 to atypical antipsychotics-like olanzapine could maximize their therapeutic efficacy while reducing their metabolic-related side effects, both by reducing the dose of antipsychotics and by a direct physiological effect of TAAR1. Unfortunately, the mechanisms by which antipsychotic drugs induce BW gain and metabolic disturbances are still poorly understood. 11, 12, 48 Antipsychotics generally affect a variety of neurotransmitter systems in the brain and periphery, many of which have been implicated in the regulation of food intake and energy homeostasis. 11, 72 The TAAR1 agonist RO5263397 prevented olanzapine from increasing food intake, presumably via centrally mediated effects. In the mouse brain, TAAR1 is expressed in a variety of areas relevant for the control of food intake and energy homeostasis, including hypothalamic nuclei, the DRN, area postrema and the nucleus of the tractus solitarius. 32 In addition, we now reveal that TAAR1 is expressed in peripheral organs directly relevant for the control of energy homeostasis and feeding, specifically, the stomach, intestine and b cells of the pancreas. Activation of TAAR1 in these organs may counteract the metabolic disturbances provoked by olanzapine through modulation of digestion, food absorption and insulin secretion.
The distinct expression of b-galactosidase in the stomach, intestine and the islets of Langerhans is well in agreement with previous reports examining TAAR1 mRNA expression in human, 16 rat 17 and mouse 49--51 tissues by reverse transcription-PCR. However, in marked contrast to the reports in human and rat, which screened for Taar1 expression in various tissues, we did not observe any expression in the heart, liver, kidney, lung, spleen or skeletal muscles. Direct detection of TAAR1 expression has proven remarkably challenging, mainly owing to its low expression levels and the absence of reliable antibodies. 19 Reverse transcription-PCR is a particularly sensitive method to detect Taar1 expression. Yet, it does not provide histological resolution and may sometimes generate false positive results, particularly for genes expressed at low levels and for intronless genes (risk of DNA contamination), both cases applying to TAAR1. In addition, as Taar1 expression has been reported in circulating blood cells of human and mouse, 73,74 contamination of tissue samples with this potential source of Taar1 mRNA cannot be excluded. The replacement of Taar1 by the LacZ reporter gene in the Taar1 À/À mouse line 32 overcomes these limitations, enabling indirect localization of Taar1 expression with good sensitivity and histological resolution. Finally, species differences in Taar1 expression cannot be ruled out.
TAAR1, a receptor with a broad action spectrum Overall, our observations show that activation of TAAR1 produces a remarkable variety of effects in psychiatric and cognitive models. This is likely to result from the close relationship between TAAR1 and monoaminergic systems, in particular through TAAR1 interaction with the D 2 and 5-HT 1A receptors and potentially also with the DA transporter. 18,21,32--34,36 Activation of TAAR1 may result in stabilization of monoaminergic neurotransmission to finetune DA and 5-HT activities. In contrast, inadequate TAAR1 activity may remove such stabilization and contribute to pathological monoaminergic activity levels. Indeed, various neuropsychiatric diseases have been associated with abnormal levels of TAs, such as PEA and pTyr, 19,22,24--28,75,76 suggesting possible roles in the etiology of those diseases. 26, 28, 29, 75 In addition, we now reveal that TAAR1 modulation alters the sleep/wake pattern, suggesting that vigilance may be affected by endogenous levels of TAs, whose levels depend on monoaminergic neuron activity and catabolism rate. 19, 24 Interestingly, only the TAAR1 partial agonist RO5263397 increased wakefulness in our studies, contrasting with the full agonist RO5256390 that did not alter the sleep/wake parameters, at least when dosed during the active phase. How exactly TAAR1 activity impacts alertness remains to be determined, but it is likely to relate to TAAR1 modulation of monoaminergic activity. CONCLUSION TAAR1 agonists represent novel and differentiated options versus existing therapies for treating schizophrenia. They display antipsychotic-like properties as potent as current antipsychotics without inducing major side effects. Their combination with current antipsychotics could improve therapeutic efficacy while reducing side effects, in particular, antipsychotic-induced weight gain and extrapyramidal symptoms. Finally, TAAR1 agonists show significant potential for improving cognitive and negative symptoms. These results in rodents and non-human primates raise new hopes for improving the condition of schizophrenic patients. Proof-of-concept studies in humans are now awaited to determine whether these findings translate into therapeutic advances.
